APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.
12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners
13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.
The Ondansetron ODF was especially designed for higher patient compliance.
Considering that the target population suffer of nausea and vomiting, Ondansetron ODF offers multiple
competitive advantages versus the already marketed pharmaceutical forms of Ondansetron:
> higher compliance vs Zofran Tablets: swallowing is easy and water is not needed
> higher compliance vs Zofran Syrup: no liquid intake and strawberry taste in the mouth, easier dosing
accuracy, shorter handling time
> higher compliance vs Zofran ODT: easier to be handled, stored and taken away
The absence of Aspartame in the formulation makes the product safe also for phenylketonuric patients,
for whom the use of Zofran ODT is contraindicated.
